Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Passes Above Two Hundred Day Moving Average of $1.29

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.29 and traded as high as $0.43. Tonix Pharmaceuticals shares last traded at $0.43, with a volume of 420 shares traded.

TNXP has been the subject of several recent research reports. ValuEngine raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Roth Capital lowered their price target on shares of Tonix Pharmaceuticals from $4.00 to $1.30 and set a “buy” rating for the company in a research note on Friday, August 30th.

The business’s 50-day simple moving average is $0.44 and its 200-day simple moving average is $1.27. The stock has a market cap of $6.91 million, a PE ratio of -0.02 and a beta of 1.30. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.01.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.01. As a group, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp will post -2.33 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. purchased a new position in shares of Tonix Pharmaceuticals in the second quarter valued at about $117,000. A.R.T. Advisors LLC purchased a new position in shares of Tonix Pharmaceuticals in the second quarter valued at about $42,000. Finally, Acadian Asset Management LLC increased its position in shares of Tonix Pharmaceuticals by 620.0% in the second quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock valued at $89,000 after acquiring an additional 56,516 shares during the period. Hedge funds and other institutional investors own 2.46% of the company’s stock.

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.

Further Reading: How to build a Fibonacci channel

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit